These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33413212)

  • 21. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
    Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
    Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
    Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
    Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
    Cazzaniga ME; Airoldi M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Blasi L; Campidoglio S; Ciccarese M; Cursano MC; Piezzo M; Fabi A; Ferrari L; Ferzi A; Ficorella C; Frassoldati A; Fumagalli A; Garrone O; Gebbia V; Generali D; La Verde N; Maur M; Michelotti A; Moretti G; Musolino A; Palumbo R; Pistelli M; Porpiglia M; Sartori D; Scavelli C; Schirone A; Turletti A; Valerio MR; Vici P; Zambelli A; Clivio L; Torri V; ;
    Breast; 2017 Oct; 35():115-121. PubMed ID: 28711793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
    Generali D; Venturini S; Rognoni C; Ciani O; Pusztai L; Loi S; Jerusalem G; Bottini A; Tarricone R
    Breast Cancer Res Treat; 2015 Jul; 152(1):95-117. PubMed ID: 26044370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
    Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
    Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
    Ciruelos E; Vidal M; Martínez de Dueñas E; Martínez-Jáñez N; Fernández Y; García-Sáenz JA; Murillo L; Carabantes F; Beliera A; Fonseca R; Gavilá J
    Clin Transl Oncol; 2018 Jun; 20(6):753-760. PubMed ID: 29116433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
    Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
    Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
    Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
    Mo H; Renna CE; Moore HCF; Abraham J; Kruse ML; Montero AJ; LeGrand SB; Wang L; Budd GT
    Clin Breast Cancer; 2022 Feb; 22(2):143-148. PubMed ID: 34740541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
    Im YH; Karabulut B; Lee KS; Park BW; Adhav A; Cinkir HY; Abdel-Razeq H; Chang YC; Aksoy S; Im SA; Jeong J; Chae Y; Bowles J; Slimane K; Xue H; Kim SB
    Breast Cancer Res Treat; 2021 Jul; 188(1):77-89. PubMed ID: 33728524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
    Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
    JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
    Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
    Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
    Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
    Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
    Ottestad L; Fronth L; Rajendiran S; Hege Aksnes L; Eikesdal HP; Støre Blix E; Ewertz M
    Acta Oncol; 2019 Mar; 58(3):385-387. PubMed ID: 30798641
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
    Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
    Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).
    Schmidt M; Lübbe K; Decker T; Thill M; Bauer L; Müller V; Link T; Furlanetto J; Reinisch M; Mundhenke C; Hoffmann O; Zahn MO; Müller L; Denkert C; van Mackelenbergh M; Fasching PA; Burchardi N; Nekljudova V; Loibl S
    ESMO Open; 2022 Dec; 7(6):100601. PubMed ID: 36356410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
    Pérez-García JM; Llombart-Cussac A; G Cortés M; Curigliano G; López-Miranda E; Alonso JL; Bermejo B; Calvo L; Carañana V; de la Cruz Sánchez S; M Vázquez R; Prat A; R Borrego M; Sampayo-Cordero M; Seguí-Palmer MÁ; Soberino J; Malfettone A; Schmid P; Cortés J
    Eur J Cancer; 2021 May; 148():382-394. PubMed ID: 33794440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
    Piccart M; Hortobagyi GN; Campone M; Pritchard KI; Lebrun F; Ito Y; Noguchi S; Perez A; Rugo HS; Deleu I; Burris HA; Provencher L; Neven P; Gnant M; Shtivelband M; Wu C; Fan J; Feng W; Taran T; Baselga J
    Ann Oncol; 2014 Dec; 25(12):2357-2362. PubMed ID: 25231953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.